Search results
Results from the WOW.Com Content Network
Prior authorization is a check run by some insurance companies or third-party payers in the United States before they will agree to cover certain prescribed medications or medical procedures. [2] There are a number of reasons that insurance providers require prior authorization, including age, medical necessity, the availability of a generic ...
He founded Sizwe & Co, KwaZulu-Natal’s first black audit firm, in 1989, and in 1996 he became the founding partner of Nkonki Sizwe Ntsaluba, now SizweNtsalubaGobodo (SNG Grant Thornton). He is the co-founder and chairman of the National Education Collaboration Trust (NECT) as a response to the call by the National Development Plan (NDP) for ...
MIB Group, Inc. or MIB (formerly the Medical Information Bureau) is a membership corporation owned by approximately 430 member insurance companies in the United States and Canada. Formed in 1902 and based in Braintree, Massachusetts , MIB provides services designed to protect insurers, policyholders, and applicants from attempts to conceal or ...
The Tanzania Commission for AIDS (TACAIDS) is the Tanzanian government organization assigned with the task of coordinating Tanzania's response to the HIV/AIDS epidemic. TACAIDS was established on 1 December 2000 in an announcement by President Benjamin Mkapa. [1] [2] Reginald Mengi is a former commissioner of TACAIDS. [3]
In most countries, a marketing authorisation is valid for a period of 5 years. After this period, one should apply for renewal of the marketing authorisation, usually by providing minimal data proving that quality, efficacy and safety characteristics are maintained and the risk-benefit ratio of the medicinal product is still favourable.
Medical underwriting is a health insurance term referring to the use of medical or health information in the evaluation of an applicant for coverage, typically for life or health insurance. As part of the underwriting process, an individual's health information may be used in making two decisions: whether to offer or deny coverage and what ...
Expanded access or compassionate use is the use of an unapproved drug or medical device under special forms of investigational new drug applications (IND) or IDE application for devices, outside of a clinical trial, by people with serious or life-threatening conditions who do not meet the enrollment criteria for the clinical trial in progress.
A centralised marketing authorisation, issued by the European Commission, allows the holder to market a medicinal product throughout the European Economic Area (EEA), which comprises the EU Member States, Iceland, Norway and Liechtenstein. [2] In the United States, the equivalent process is called New Drug Application.